Literature DB >> 22014569

Resistance to EGFR-targeted therapy: a family affair.

Gregory Vlacich1, Robert J Coffey.   

Abstract

The EGFR-directed antibody cetuximab has proven, albeit modest, clinical benefit as monotherapy in head and neck and colorectal cancers. In a recent study, Yonesaka et al. uncovered a new mechanism of cetuximab resistance mediated by increased ERBB2 signaling via amplification of ERBB2 or increased levels of the ERBB3/ERBB4 ligand heregulin.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Year:  2011        PMID： 22014569      PMCID： PMC3616495          DOI： 10.1016/j.ccr.2011.10.006

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

1.  The mutational landscape of head and neck squamous cell carcinoma.

Authors:  Nicolas Stransky; Ann Marie Egloff; Aaron D Tward; Aleksandar D Kostic; Kristian Cibulskis; Andrey Sivachenko; Gregory V Kryukov; Michael S Lawrence; Carrie Sougnez; Aaron McKenna; Erica Shefler; Alex H Ramos; Petar Stojanov; Scott L Carter; Douglas Voet; Maria L Cortés; Daniel Auclair; Michael F Berger; Gordon Saksena; Candace Guiducci; Robert C Onofrio; Melissa Parkin; Marjorie Romkes; Joel L Weissfeld; Raja R Seethala; Lin Wang; Claudia Rangel-Escareño; Juan Carlos Fernandez-Lopez; Alfredo Hidalgo-Miranda; Jorge Melendez-Zajgla; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Matthew Meyerson; Eric S Lander; Gad Getz; Todd R Golub; Levi A Garraway; Jennifer R Grandis
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

2.  Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance.

Authors:  Kelly M Quesnelle; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2011-07-26       Impact factor: 12.531

3.  Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.

Authors:  Kimio Yonesaka; Kreshnik Zejnullahu; Isamu Okamoto; Taroh Satoh; Federico Cappuzzo; John Souglakos; Dalia Ercan; Andrew Rogers; Massimo Roncalli; Masayuki Takeda; Yasuhito Fujisaka; Juliet Philips; Toshio Shimizu; Osamu Maenishi; Yonggon Cho; Jason Sun; Annarita Destro; Koichi Taira; Koji Takeda; Takafumi Okabe; Jeffrey Swanson; Hiroyuki Itoh; Minoru Takada; Eugene Lifshits; Kiyotaka Okuno; Jeffrey A Engelman; Ramesh A Shivdasani; Kazuto Nishio; Masahiro Fukuoka; Marileila Varella-Garcia; Kazuhiko Nakagawa; Pasi A Jänne
Journal:  Sci Transl Med       Date:  2011-09-07       Impact factor: 17.956

4.  A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.

Authors:  Carlos L Arteaga; Anne O'Neill; Stacy L Moulder; Michael Pins; Joseph A Sparano; George W Sledge; Nancy E Davidson
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

5.  Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo.

Authors:  Ella Atlas; Marina Cardillo; Inderjit Mehmi; Hengameh Zahedkargaran; Careen Tang; Ruth Lupu
Journal:  Mol Cancer Res       Date:  2003-01       Impact factor: 5.852

6.  Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.

Authors:  Nicola Personeni; Steffen Fieuws; Hubert Piessevaux; Gert De Hertogh; Jef De Schutter; Bart Biesmans; Wendy De Roock; An Capoen; Maria Debiec-Rychter; Jean-Luc Van Laethem; Marc Peeters; Yves Humblet; Eric Van Cutsem; Sabine Tejpar
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

7.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

Authors:  Shirin Khambata-Ford; Christopher R Garrett; Neal J Meropol; Mark Basik; Christopher T Harbison; Shujian Wu; Tai W Wong; Xin Huang; Chris H Takimoto; Andrew K Godwin; Benjamin R Tan; Smitha S Krishnamurthi; Howard A Burris; Elizabeth A Poplin; Manuel Hidalgo; Jose Baselga; Edwin A Clark; David J Mauro
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

8.  MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Authors:  Jeffrey A Engelman; Kreshnik Zejnullahu; Tetsuya Mitsudomi; Youngchul Song; Courtney Hyland; Joon Oh Park; Neal Lindeman; Christopher-Michael Gale; Xiaojun Zhao; James Christensen; Takayuki Kosaka; Alison J Holmes; Andrew M Rogers; Federico Cappuzzo; Tony Mok; Charles Lee; Bruce E Johnson; Lewis C Cantley; Pasi A Jänne
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

9.  Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.

Authors:  Christoph A Ritter; Marianela Perez-Torres; Cammie Rinehart; Marta Guix; Teresa Dugger; Jeffrey A Engelman; Carlos L Arteaga
Journal:  Clin Cancer Res       Date:  2007-08-15       Impact factor: 12.531

10.  A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

Authors:  Andrea Bertotti; Giorgia Migliardi; Francesco Galimi; Francesco Sassi; Davide Torti; Claudio Isella; Davide Corà; Federica Di Nicolantonio; Michela Buscarino; Consalvo Petti; Dario Ribero; Nadia Russolillo; Andrea Muratore; Paolo Massucco; Alberto Pisacane; Luca Molinaro; Emanuele Valtorta; Andrea Sartore-Bianchi; Mauro Risio; Lorenzo Capussotti; Marcello Gambacorta; Salvatore Siena; Enzo Medico; Anna Sapino; Silvia Marsoni; Paolo M Comoglio; Alberto Bardelli; Livio Trusolino
Journal:  Cancer Discov       Date:  2011-09-02       Impact factor: 39.397
  10 in total
  24 in total

1.  Generation and Characterization of Rat Monoclonal Antibodies Against Epidermal Growth Factor Receptor.

Authors:  Tomohiro Osaki; Cai-Xia Wang; Taro Tachibana; Masayuki Azuma; Masaya Kitamura; Takeshi Nakanishi
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-12

2.  HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.

Authors:  Dongsheng Wang; Guoqing Qian; Hongzheng Zhang; Kelly R Magliocca; Sreenivas Nannapaneni; A R M Ruhul Amin; Michael Rossi; Mihir Patel; Mark El-Deiry; J Trad Wadsworth; Zhengjia Chen; Fadlo R Khuri; Dong M Shin; Nabil F Saba; Zhuo G Chen
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

3.  Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.

Authors:  Aparna Parikh; Chloe Atreya; W Michael Korn; Alan P Venook
Journal:  J Natl Compr Canc Netw       Date:  2017-01       Impact factor: 11.908

Review 4.  Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease.

Authors:  Helena M Kok; Lucas L Falke; Roel Goldschmeding; Tri Q Nguyen
Journal:  Nat Rev Nephrol       Date:  2014-10-14       Impact factor: 28.314

5.  A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism.

Authors:  Zhi Liu; Esther C Leng; Kannan Gunasekaran; Martin Pentony; Min Shen; Monique Howard; Janelle Stoops; Kathy Manchulenko; Vladimir Razinkov; Hua Liu; William Fanslow; Zhonghua Hu; Nancy Sun; Haruki Hasegawa; Rutilio Clark; Ian N Foltz; Wei Yan
Journal:  J Biol Chem       Date:  2015-01-12       Impact factor: 5.157

6.  An EGFR/PI3K/AKT axis promotes accumulation of the Rac1-GEF Tiam1 that is critical in EGFR-driven tumorigenesis.

Authors:  G Zhu; Z Fan; M Ding; H Zhang; L Mu; Y Ding; Y Zhang; B Jia; L Chen; Z Chang; W Wu
Journal:  Oncogene       Date:  2015-03-09       Impact factor: 9.867

7.  HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells.

Authors:  Megan Jo Miller; Kevin C Foy; Jay P Overholser; Rita Nahta; Pravin Tp Kaumaya
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

8.  Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.

Authors:  Ning Jiang; Dongsheng Wang; Zhongliang Hu; Hyung Ju C Shin; Guoqing Qian; Mohammad Aminur Rahman; Hongzheng Zhang; A R M Ruhul Amin; Sreenivas Nannapaneni; Xiaojing Wang; Zhengjia Chen; Gabriela Garcia; Gavin MacBeath; Dong M Shin; Fadlo R Khuri; Jun Ma; Zhuo G Chen; Nabil F Saba
Journal:  Mol Cancer Ther       Date:  2014-04-18       Impact factor: 6.261

9.  Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.

Authors:  Mari Iida; Harsh Bahrar; Toni M Brand; Hannah E Pearson; John P Coan; Rachel A Orbuch; Bailey G Flanigan; Adam D Swick; Prashanth J Prabakaran; Johan Lantto; Ivan D Horak; Michael Kragh; Ravi Salgia; Randy J Kimple; Deric L Wheeler
Journal:  Mol Cancer Ther       Date:  2016-07-15       Impact factor: 6.261

10.  Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.

Authors:  Shyhmin Huang; Chunrong Li; Eric A Armstrong; Chimera R Peet; Jarob Saker; Lukas C Amler; Mark X Sliwkowski; Paul M Harari
Journal:  Cancer Res       Date:  2012-11-20       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.